Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

Wen, 2017, Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges, J. Control. Release, 245, 95, 10.1016/j.jconrel.2016.11.025 Lista, 2015, Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies, J. Nutr. Health Aging, 19, 154, 10.1007/s12603-014-0515-3 2015 Alzheimer's disease facts and figures, 2015, Alzheimer's & dementia, J. Alzheimer's Assoc., 11, 332 Folch, 2016, Current research therapeutic strategies for Alzheimer’s disease treatment, Neural Plast., 2016, 15, 10.1155/2016/8501693 Fettelschoss, 2014, Vaccination against Alzheimer disease: an update on future strategies, Hum. Vaccines Immunotherapeutics, 10, 847, 10.4161/hv.28183 Prince, 2016, Improving healthcare for people living with dementia, 140 2017 Alzheimer's disease facts and figures, 2017, vol. 13, 325 Mohammadi, 2011, Modulation of H2O2-induced mitogen-activated protein kinases activation and cell death in SK-N-MC cells by EUK134, a salen derivative, Basic Clin. Pharmacol. Toxicol., 108, 378, 10.1111/j.1742-7843.2010.00664.x Di Stefano, 2011, Drug delivery strategies for Alzheimer's disease treatment, Expert Opin. Drug Deliv., 8, 581, 10.1517/17425247.2011.561311 Brambilla, 2012, PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease, ACS Nano, 6, 5897, 10.1021/nn300489k Parihar, 2004, Alzheimer's disease pathogenesis and therapeutic interventions, J. Clin. Neurosci., 11, 456, 10.1016/j.jocn.2003.12.007 Agrawal, 2018, Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region, Expert Opin. Drug Deliv., 10.1080/17425247.2018.1471058 Nagpal, 2013, Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB, Expert Opin. Drug Deliv., 10, 927, 10.1517/17425247.2013.762354 Begley, 2004, Delivery of therapeutic agents to the central nervous system: the problems and the possibilities, Pharmacol. Ther., 104, 29, 10.1016/j.pharmthera.2004.08.001 Brasnjevic, 2009, Delivery of peptide and protein drugs over the blood-brain barrier, Prog. Neurobiol., 87, 212, 10.1016/j.pneurobio.2008.12.002 Su, 2006, Drug delivery across the blood–brain barrier: why is it difficult? How to measure and improve it?, Expert Opin. Drug Deliv., 3, 419, 10.1517/17425247.3.3.419 Agrawal, 2017, Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease, J. Control. Release, 260, 61, 10.1016/j.jconrel.2017.05.019 Lochhead, 2015, Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration, J. Cereb. Blood Flow Metab., 35, 371, 10.1038/jcbfm.2014.215 van Sorge, 2012, Defense at the border: the blood-brain barrier versus bacterial foreigners, Future Microbiol, 7, 383, 10.2217/fmb.12.1 Bitter, 2011, Nasal drug delivery in humans, Curr. Probl. Dermatol., 40, 20, 10.1159/000321044 Jiang, 2011, Intranasal delivery of stem cells to the brain, Expert Opin. Drug Deliv., 8, 623, 10.1517/17425247.2011.566267 Chapman, 2013, Intranasal treatment of central nervous system dysfunction in humans, Pharm. Res., 30, 2475, 10.1007/s11095-012-0915-1 Frey, 1997, Delivery of 125I-NGF to the brain via the olfactory route, Drug Deliv., 4, 87, 10.3109/10717549709051878 Chen, 1998, Delivery of nerve growth factor to the brain via the olfactory pathway, J. Alzheimer's Dis., 1, 35, 10.3233/JAD-1998-1102 Lochhead, 2012, Intranasal delivery of biologics to the central nervous system, Adv. Drug Deliv. Rev., 64, 614, 10.1016/j.addr.2011.11.002 Danielyan, 2009, Intranasal delivery of cells to the brain, Eur. J. Cell Biol., 88, 315, 10.1016/j.ejcb.2009.02.001 Danielyan, 2011, Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease, Rejuvenation Res., 14, 3, 10.1089/rej.2010.1130 Kulkarni, 2011, Modulation of anxiety behavior by intranasally administered vaccinia virus complement control protein and curcumin in a mouse model of Alzheimer's disease, Curr. Alzheimer Res., 8, 95, 10.2174/156720511794604598 Hussain, 1998, Intranasal drug delivery, Adv. Drug Deliv. Rev., 29, 39, 10.1016/S0169-409X(97)00060-4 Sood, 2014, Intranasal therapeutic strategies for management of Alzheimer's disease, J. Drug Target., 22, 279, 10.3109/1061186X.2013.876644 Fortuna, 2014, Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules, Eur. J. Pharm. Biopharm., 88, 8, 10.1016/j.ejpb.2014.03.004 Grassin-Delyle, 2012, Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids, Pharmacol. Ther., 134, 366, 10.1016/j.pharmthera.2012.03.003 Kisan, 2007, Nasal drug delivery system-factors affecting and applications, Curr. Drug Ther., 2, 27, 10.2174/157488507779422374 II, 1991 Frey, 2012 van den Berg, 2004, Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study, Pharm. Res., 21, 799, 10.1023/B:PHAM.0000026431.55383.69 Al-Ghananeem, 2002, Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs, AAPS PharmSciTech, 3, 10.1208/pt030105 Dhuria, 2010, Intranasal delivery to the central nervous system: mechanisms and experimental considerations, J. Pharm. Sci., 99, 1654, 10.1002/jps.21924 Hanafy, 2016, Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management, Drug Deliv., 23, 3111, 10.3109/10717544.2016.1153748 Hanafy, 2015, Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain, Drug Dev. Ind. Pharm., 41, 2055, 10.3109/03639045.2015.1062897 Bhattacharya, 2015, Nasal application of the Galantamine pro-drug Memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice, J. Alzheimer's Dis., 46, 123, 10.3233/JAD-142421 Li, 2012, Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes, Environ. Toxicol. Pharmacol., 34, 272, 10.1016/j.etap.2012.04.012 Yang, 2013, Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration, Int. J. Pharm., 452, 344, 10.1016/j.ijpharm.2013.05.009 Fazil, 2012, Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting, Eur. J. Pharm. Sci., 47, 6, 10.1016/j.ejps.2012.04.013 Liu, 2013, Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration, Biomaterials, 34, 3870, 10.1016/j.biomaterials.2013.02.003 Maurice, 2013, Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(−)(3)(5) non-transgenic mouse model of Alzheimer's disease, J. Psychopharmacol., 27, 1044, 10.1177/0269881113494939 Feng, 2012, Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of beta-amyloid and ibotenic acid into the bilateral hippocampus, Int. J. Pharm., 423, 226, 10.1016/j.ijpharm.2011.12.008 Zhang, 2014, Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease, Int. J. Pharm., 461, 192, 10.1016/j.ijpharm.2013.11.049 Gao, 2007, Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration, J. Control. Release, 121, 156, 10.1016/j.jconrel.2007.05.026 Picone, 2016, Ionizing radiation-engineered nanogels as insulin nanocarriers for the development of a new strategy for the treatment of Alzheimer's disease, Biomaterials, 80, 179, 10.1016/j.biomaterials.2015.11.057 Chen, 2014, Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice, Exp. Neurol., 261, 610, 10.1016/j.expneurol.2014.06.004 Mao, 2016, Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice, Aging Cell, 15, 893, 10.1111/acel.12498 Salameh, 2015, Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition, J. Alzheimer's Dis., 47, 715, 10.3233/JAD-150307 Craft, 2012, Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial, Arch. Neurol., 69, 29, 10.1001/archneurol.2011.233 Wu, 2012, A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-beta(2)(5)(−)(3)(5)-treated rats following intranasal administration, Eur. J. Pharm. Biopharm., 80, 368, 10.1016/j.ejpb.2011.10.012 Qian, 2014, Development, characterization and application of in situ gel systems for intranasal delivery of tacrine, Int. J. Pharm., 468, 272, 10.1016/j.ijpharm.2014.04.015 Bhavna, 2014, Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation, Int. J. Biol. Macromol., 67, 418, 10.1016/j.ijbiomac.2014.03.022 Meng, 2018, Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease, Int. J. Nanomedicine, 13, 705, 10.2147/IJN.S151474 Wang, 2011, Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model, Neuropsychopharmacology, 36, 1073, 10.1038/npp.2010.245 Kumar, 2008, Intranasal nanoemulsion based brain targeting drug delivery system of risperidone, Int. J. Pharm., 358, 285, 10.1016/j.ijpharm.2008.03.029 Elnaggar, 2015, Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity, J. Pharm. Sci., 104, 3544, 10.1002/jps.24557 Lin, 2016, Intranasal Administration of a Polyethylenimine-Conjugated Scavenger Peptide Reduces Amyloid-beta Accumulation in a mouse model of Alzheimer's disease, J. Alzheimer's Dis., 53, 1053, 10.3233/JAD-151024 Guo, 2013, Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease, Neurobiol. Aging, 34, 562, 10.1016/j.neurobiolaging.2012.05.009 Fine, 2015, Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation, Neurosci. Lett., 584, 362, 10.1016/j.neulet.2014.11.013 Hanson, 2012, Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice, Drug Deliv. Transl. Res., 2, 160, 10.1007/s13346-011-0050-2 Guo, 2015, Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1alpha pathway on the brain of APP/PS1 transgenic mice, Front. Aging Neurosci., 7, 104, 10.3389/fnagi.2015.00104 Muntimadugu, 2016, Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease, Eur. J. Pharm. Sci., 92, 224, 10.1016/j.ejps.2016.05.012 Zheng, 2015, Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer's disease, Pharm. Res., 32, 3837, 10.1007/s11095-015-1744-9 Yang, 2014, Enhancement of the nonamyloidogenic pathway by exogenous NGF in an Alzheimer transgenic mouse model, Neuropeptides, 48, 233, 10.1016/j.npep.2014.04.005 Capsoni, 2012, Intranasal "painless" human nerve growth factor [corrected] slows amyloid neurodegeneration and prevents memory deficits in app X PS1 mice, PLoS One, 7, 10.1371/annotation/97b6c799-1ebc-4e7b-8f86-47c1130dc00e Capsoni, 2009, Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice, J. Alzheimer's Dis., 16, 371, 10.3233/JAD-2009-0953 De Rosa, 2005, Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice, Proc. Natl. Acad. Sci. U. S. A., 102, 3811, 10.1073/pnas.0500195102 Vaz, 2017, Development of nasal lipid nanocarriers containing curcumin for brain targeting, J. Alzheimers Dis., 59, 961, 10.3233/JAD-160355 Chen, 2013, Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel, J. Pharm. Pharmacol., 65, 807, 10.1111/jphp.12043 Wang, 2012, Formulation and evaluation of microemulsion-based in situ ion-sensitive gelling systems for intranasal administration of curcumin, J. Drug Target., 20, 831, 10.3109/1061186X.2012.719230 Lungare, 2016, Phytochemical-loaded mesoporous silica nanoparticles for nose-to-brain olfactory drug delivery, Int. J. Pharm., 513, 280, 10.1016/j.ijpharm.2016.09.042 Nasr, 2016, Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery, Drug Deliv., 23, 1444, 10.3109/10717544.2015.1092619 Crowe, 2018, Mechanism of intranasal drug delivery directly to the brain, Life Sci., 195, 44, 10.1016/j.lfs.2017.12.025 Merkus, 1998, Nasal mucociliary clearance as a factor in nasal drug delivery, Adv. Drug Deliv. Rev., 29, 13, 10.1016/S0169-409X(97)00059-8 Vyas, 2006, Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting, J. Pharm. Sci., 95, 570, 10.1002/jps.20480 William, 2016, Intranasal drug delivery bypasses the blood–brain barrier, Neurol. Rev., 24, 40 Einer-Jensen, 2005, Counter-current transfer in reproductive biology, Reproduction (Cambridge, England), 129, 9, 10.1530/rep.1.00278 Illum, 2000, Transport of drugs from the nasal cavity to the central nervous system, Eur. J. Pharm. Sci., 11, 1, 10.1016/S0928-0987(00)00087-7 Kristensson, 1971, Uptake of exogenous proteins in mouse olfactory cells, Acta Neuropathol., 19, 145, 10.1007/BF00688493 Alexander, 2012, Approaches for breaking the barriers of drug permeation through transdermal drug delivery, J. Control. Release, 164, 26, 10.1016/j.jconrel.2012.09.017 Florence, 1997, The oral absorption of micro- and nanoparticulates: neither exceptional nor unusual, Pharm. Res., 14, 259, 10.1023/A:1012029517394 Lockman, 2002, Nanoparticle technology for drug delivery across the blood-brain barrier, Drug Dev. Ind. Pharm., 28, 1, 10.1081/DDC-120001481 Ugwoke, 2001, The biopharmaceutical aspects of nasal mucoadhesive drug delivery, J. Pharm. Pharmacol., 53, 3, 10.1211/0022357011775145 Pires, 2018, Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies, J. Control. Release, 270, 89, 10.1016/j.jconrel.2017.11.047 Scheibe, 2008, Intranasal administration of drugs, Arch. Otolaryngol., 134, 643, 10.1001/archotol.134.6.643 Djupesland, 2006, Breath actuated device improves delivery to target sites beyond the nasal valve, Laryngoscope, 116, 466, 10.1097/01.MLG.0000199741.08517.99 Reger, 2008, Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults, J. Alzheimer's Dis., 13, 323, 10.3233/JAD-2008-13309 Van den Berg, 2003, Hydroxocobalamin uptake into the cerebrospinal fluid after nasal and intravenous delivery in rats and humans, J. Drug Target., 11, 325, 10.1080/10611860310001640075 Kumar, 2008, Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting, J. Drug Target., 16, 806, 10.1080/10611860802476504 Alexander, 2016, Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives, J. Control. Release, 241, 110, 10.1016/j.jconrel.2016.09.017 Bhattacharya, 2014, Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease, PLoS One, 9, 10.1371/journal.pone.0089454 Atanasova, 2015, Galantamine derivatives with indole moiety: docking, design, synthesis and acetylcholinesterase inhibitory activity, Bioorg. Med. Chem., 23, 5382, 10.1016/j.bmc.2015.07.058 Farlow, 2001, Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine, Clin. Ther., 23, A13, 10.1016/S0149-2918(01)80164-8 Contestabile, 2011, The history of the cholinergic hypothesis, Behav. Brain Res., 221, 334, 10.1016/j.bbr.2009.12.044 Patel, 2011, Combination therapy for Alzheimer's disease, Drugs Aging, 28, 539, 10.2165/11591860-000000000-00000 Ezoulin, 2008, Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells, Neurotoxicology, 29, 270, 10.1016/j.neuro.2007.11.004 de Bruin, 2006, Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval, Pharmacol. Biochem. Behav., 85, 253, 10.1016/j.pbb.2006.08.007 Oh, 2006, Skin permeation of retinol in tween 20-based deformable liposomes: in-vitro evaluation in human skin and keratinocyte models, J. Pharm. Pharmacol., 58, 161, 10.1211/jpp.58.2.0002 Matharu, 2009, Galantamine inhibits beta-amyloid aggregation and cytotoxicity, J. Neurol. Sci., 280, 49, 10.1016/j.jns.2009.01.024 Zhang, 2004, Galantamine blocks cloned Kv2.1, but not Kv1.5 potassium channels, brain research, Mol. Brain Res., 131, 136, 10.1016/j.molbrainres.2004.08.010 Chen, 2012, Modern methods for delivery of drugs across the blood–brain barrier, Adv. Drug Deliv. Rev., 64, 640, 10.1016/j.addr.2011.11.010 Galgatte, 2014, Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation, Drug Deliv., 21, 62, 10.3109/10717544.2013.849778 Bhatt, 2015, Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease, Drug Deliv., 22, 931, 10.3109/10717544.2014.880860 Ravi, 2015, Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization, Drug Deliv., 22, 903, 10.3109/10717544.2013.860501 Elgadir, 2015, Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review, J. Food Drug Anal., 23, 619, 10.1016/j.jfda.2014.10.008 Ong, 2014, Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders, Curr. Med. Chem., 21, 4247, 10.2174/0929867321666140716103130 Baldrick, 2010, The safety of chitosan as a pharmaceutical excipient, Regul. Toxicol. Pharmacol., 56, 290, 10.1016/j.yrtph.2009.09.015 Bamrungsap, 2012, Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system, Nanomedicine (London, England), 7, 1253, 10.2217/nnm.12.87 Alexander, 2015, A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates, Drug Dev. Ind. Pharm., 41, 1954, 10.3109/03639045.2015.1011167 Alexander, 2014, Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate, J. Pharm. Pharmacol., 66, 1240, 10.1111/jphp.12262 Dash, 2010, Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm., 67, 217 Maelicke, 2010, Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy, J. Mol. Neurosci., 40, 135, 10.1007/s12031-009-9269-5 Cicinelli, 1996, Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women, J. Endocrinol. Investig., 19, 427, 10.1007/BF03349887 Anand, 2014, Therapeutics of Alzheimer's disease: past, present and future, Neuropharmacology, 76, 27, 10.1016/j.neuropharm.2013.07.004 Costantino, 2007, Intranasal delivery: physicochemical and therapeutic aspects, Int. J. Pharm., 337, 1, 10.1016/j.ijpharm.2007.03.025 Touitou, 2000, Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties, J. Control. Release, 65, 403, 10.1016/S0168-3659(99)00222-9 Touitou, 2001, Intracellular delivery mediated by an ethosomal carrier, Biomaterials, 22, 3053, 10.1016/S0142-9612(01)00052-7 Elsayed, 2006, Deformable liposomes and ethosomes: mechanism of enhanced skin delivery, Int. J. Pharm., 322, 60, 10.1016/j.ijpharm.2006.05.027 Oh, 2006, Galantamine increases excitability of CA1 hippocampal pyramidal neurons, Neuroscience, 137, 113, 10.1016/j.neuroscience.2005.08.063 Lee, 2005, Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes, Biomaterials, 26, 205, 10.1016/j.biomaterials.2004.02.020 Elsayed, 2007, Deformable liposomes and ethosomes as carriers for skin delivery of ketotifen, Die Pharmazie, 62, 133 Jain, 2003, Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation, Drug Dev. Ind. Pharm., 29, 1013, 10.1081/DDC-120025458 Hallschmid, 2008, Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders, Regul. Pept., 149, 79, 10.1016/j.regpep.2007.06.012 Rodrigues Simoes, 2014, Donepezil: an important prototype to the design of new drug candidates for Alzheimer's disease, Mini Rev. Med. Chem., 14, 2, 10.2174/1389557513666131119201353 Kása, 1997, The cholinergic system in Alzheimer's disease, Prog. Neurobiol., 52, 511, 10.1016/S0301-0082(97)00028-2 Noetzli, 2013, Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease, Clin. Pharmacokinet., 52, 225, 10.1007/s40262-013-0038-9 Calvo, 1997, Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines, Pharm. Res., 14, 1431, 10.1023/A:1012128907225 Spencer, 1998, Rivastigmine. A review of its use in Alzheimer's disease, Drugs Aging, 13, 391, 10.2165/00002512-199813050-00005 Gauthier, 2006, Aggressive course of disease in dementia, Alzheimer's Dement., 2, 210, 10.1016/j.jalz.2006.03.002 Cummings, 2007, Pharmacokinetic rationale for the rivastigmine patch, Neurology, 69, S10, 10.1212/01.wnl.0000281846.40390.50 Tenovuo, 2005, Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 29, 61, 10.1016/j.pnpbp.2004.10.006 Venkatesh, 2007, Strategies to improve tolerability of rivastigmine: a case series, Curr. Med. Res. Opin., 23, 93, 10.1185/030079906X162791 Ali, 2015, Adverse effects of cholinesterase inhibitors in dementia, according to the Pharmacovigilance databases of the United-States and Canada, PLoS One, 10, 10.1371/journal.pone.0144337 Trabulo, 2010, Cell-penetrating peptides-mechanisms of cellular uptake and generation of delivery systems, Pharmaceuticals (Basel, Switzerland), 3, 961, 10.3390/ph3040961 Zhang, 2009, Endocytosis and membrane potential are required for HeLa cell uptake of R.I.-CKTat9, a retro-inverso tat cell penetrating peptide, Mol. Pharm., 6, 836, 10.1021/mp800121f Ma, 2011, Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells, Int. J. Pharm., 419, 200, 10.1016/j.ijpharm.2011.08.001 Torchilin, 2008, Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers, Adv. Drug Deliv. Rev., 60, 548, 10.1016/j.addr.2007.10.008 Vila, 2002, Design of biodegradable particles for protein delivery, J. Control. Release, 78, 15, 10.1016/S0168-3659(01)00486-2 Aktaş, 2005, Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor, Int. J. Pharm., 298, 378, 10.1016/j.ijpharm.2005.03.027 Ritger, 1987, A simple equation for description of solute release II. Fickian and anomalous release from swellable devices, J. Control. Release, 5, 37, 10.1016/0168-3659(87)90035-6 Porporatto, 2005, Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration, J. Leukoc. Biol., 78, 62, 10.1189/jlb.0904541 Borchard, 1996, The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro, J. Control. Release, 39, 131, 10.1016/0168-3659(95)00146-8 Tosi, 2007, Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123, J. Control. Release, 122, 1, 10.1016/j.jconrel.2007.05.022 Vergoni, 2009, Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution, Nanomedicine, 5, 369, 10.1016/j.nano.2009.02.005 Taraschenko, 2005, Actions of tacrine and galanthamine on histamine-N-methyltransferase, Methods Find. Exp. Clin. Pharmacol., 27, 161, 10.1358/mf.2005.27.3.890872 FDA, 2018, Drug database Hartvig, 1990, Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine, Eur. J. Clin. Pharmacol., 38, 259, 10.1007/BF00315027 Madden, 1995, Clinical pharmacokinetics of tacrine, Clin. Pharmacokinet., 28, 449, 10.2165/00003088-199528060-00003 O'Brien, 1991, Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease, Age Ageing, 20, 129, 10.1093/ageing/20.2.129 Qizilbash, 1998, Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' collaboration, JAMA, 280, 1777, 10.1001/jama.280.20.1777 Patocka, 2008, Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease, Curr. Drug Metab., 9, 332, 10.2174/138920008784220619 Wong, 2010, Intranasal delivery—modification of drug metabolism and brain disposition, Pharm. Res., 27, 1208, 10.1007/s11095-010-0127-5 Jogani, 2008, Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting, Alzheimer Dis. Assoc. Disord., 22, 116, 10.1097/WAD.0b013e318157205b Illum, 2002, Intranasal delivery of morphine, J. Pharmacol. Exp. Ther., 301, 391, 10.1124/jpet.301.1.391 Watts, 2009, PecSys: in situ gelling system for optimised nasal drug delivery, Expert Opin. Drug Deliv., 6, 543, 10.1517/17425240902939135 Anderson, 2001, Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels, J. Control. Release, 70, 157, 10.1016/S0168-3659(00)00341-2 Jeong, 2002, Thermosensitive sol-gel reversible hydrogels, Adv. Drug Deliv. Rev., 54, 37, 10.1016/S0169-409X(01)00242-3 Li, 2011, Thermosensitive hydrogels for drug delivery, Expert Opin. Drug Deliv., 8, 991, 10.1517/17425247.2011.581656 Alexander, 2014, Saraf, polyethylene glycol (PEG)-poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications, Eur. J. Pharm. Biopharm., 88, 575, 10.1016/j.ejpb.2014.07.005 Escobar-Chavez, 2006, Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations, J. Pharm. Pharm. Sci., 9, 339 Ruel-Gariepy, 2004, In situ-forming hydrogels—review of temperature-sensitive systems, Eur. J. Pharm. Biopharm., 58, 409, 10.1016/j.ejpb.2004.03.019 Gilbert, 1986, Drug release from Pluronic F-127 gels, Int. J. Pharm., 32, 223, 10.1016/0378-5173(86)90182-1 Baloglu, 2011, In-situ gel formulations of econazole nitrate: preparation and in-vitro and in-vivo evaluation, J. Pharm. Pharmacol., 63, 1274, 10.1111/j.2042-7158.2011.01315.x Jitendra, 2008, In situ mucoadhesive nasal gels of metoclopramide hydrochloride: preformulation and formulation studies, J. Pharm. Res., 1, 88 Bhandwalkar, 2013, Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation, AAPS PharmSciTech, 14, 101, 10.1208/s12249-012-9893-1 Yun, 1999, Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement, Int. J. Pharm., 189, 137, 10.1016/S0378-5173(99)00227-6 Bhalerao, 2009, Nasal Mucoadhesive in situ gel of ondansetron hydrochloride, Indian J. Pharm. Sci., 71, 711 Chen, 2010, Preparation of nasal temperature-sensitive in situ gel of Radix Bupleuri and evaluation of the febrile response mechanism, Drug Dev. Ind. Pharm., 36, 490, 10.3109/03639040903264371 Majithiya, 2006, Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan, AAPS PharmSciTech, 67 Moore, 2000, Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: drug release in stirred systems, J. Control. Release, 67, 191, 10.1016/S0168-3659(00)00215-7 Cho, 2011, Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride, J. Pharm. Sci., 100, 681, 10.1002/jps.22314 Sharma, 2012, Efficacy of Risperidone in managing maladaptive behaviors for children with autistic Spectrum disorder: a meta-analysis, J. Pediatr. Health Care, 26, 291, 10.1016/j.pedhc.2011.02.008 2014 Vyas, 2005, Intranasal drug delivery for brain targeting, Curr. Drug Deliv., 2, 165, 10.2174/1567201053586047 Mathison, 1998, Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?, J. Drug Target., 5, 415, 10.3109/10611869808997870 Chow, 1999, Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats, J. Pharm. Sci., 88, 754, 10.1021/js9900295 Zhang, 2004, Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain, Int. J. Pharm., 275, 85, 10.1016/j.ijpharm.2004.01.039 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science (New York, N.Y.), 297, 353, 10.1126/science.1072994 Walsh, 2002, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature, 416, 535, 10.1038/416535a Bush, 2003, The metallobiology of Alzheimer's disease, Trends Neurosci., 26, 207, 10.1016/S0166-2236(03)00067-5 Lovell, 1998, Copper, iron and zinc in Alzheimer's disease senile plaques, J. Neurol. Sci., 158, 47, 10.1016/S0022-510X(98)00092-6 Strozyk, 2009, Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid, Neurobiol. Aging, 30, 1069, 10.1016/j.neurobiolaging.2007.10.012 Zhang, 2010, Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain, Neurobiol. Aging, 31, 74, 10.1016/j.neurobiolaging.2008.02.018 Atwood, 2003, Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta, Brain Res. Brain Res. Rev., 43, 1, 10.1016/S0165-0173(03)00174-7 Jiang, 2009, Ternary complexes of iron, amyloid-beta, and nitrilotriacetic acid: binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease, Biochemistry, 48, 7939, 10.1021/bi900907a Moreira, 2010, Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease, Methods Mol. Biol. (Clifton, N.J.), 610, 419, 10.1007/978-1-60327-029-8_25 Castellani, 2004, Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease, Ageing Res. Rev., 3, 319, 10.1016/j.arr.2004.01.002 Lovell, 2004, Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3, J. Alzheimer's Dis., 6, 659, 10.3233/JAD-2004-6610 Pratico, 2000, Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease, Am. J. Med., 109, 577, 10.1016/S0002-9343(00)00547-7 Sayre, 2001, Chemistry and biochemistry of oxidative stress in neurodegenerative disease, Curr. Med. Chem., 8, 721, 10.2174/0929867013372922 Cherny, 2001, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8 Crapper McLachlan, 1991, Intramuscular desferrioxamine in patients with Alzheimer's disease, Lancet (London, England), 337, 1304, 10.1016/0140-6736(91)92978-B Whitnall, 2006, Iron: a new target for pharmacological intervention in neurodegenerative diseases, Semin. Pediatr. Neurol., 13, 186, 10.1016/j.spen.2006.08.008 House, 2004, Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease, J. Alzheimer's Dis., 6, 291, 10.3233/JAD-2004-6310 Morse, 2004, FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein, J. Mol. Neurosci., 24, 129, 10.1385/JMN:24:1:129 Avramovich-Tirosh, 2007, Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG, Curr. Alzheimer Res., 4, 403, 10.2174/156720507781788927 Cuajungco, 2000, Metal chelation as a potential therapy for Alzheimer's disease, Ann. N. Y. Acad. Sci., 920, 292, 10.1111/j.1749-6632.2000.tb06938.x Freedman, 1988, Neurotoxicity associated with deferoxamine therapy, Toxicology, 49, 283, 10.1016/0300-483X(88)90010-8 Lindner, 1995, Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth, Int. J. Cancer, 63, 592, 10.1002/ijc.2910630421 Shachar, 2004, Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats, Neuropharmacology, 46, 254, 10.1016/j.neuropharm.2003.09.005 May, 1983, 5 the present status of chelating agents in medicine, 225, 10.1016/S0079-6468(08)70220-0 Hanson, 2009, Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke, J. Pharmacol. Exp. Ther., 330, 679, 10.1124/jpet.108.149807 Esch, 1990, Cleavage of amyloid beta peptide during constitutive processing of its precursor, Science (New York, N.Y.), 248, 1122, 10.1126/science.2111583 Arendash, 2004, Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain, Brain Res., 1012, 29, 10.1016/j.brainres.2004.02.081 Cai, 2012, Roles of glycogen synthase kinase 3 in Alzheimer's disease, Curr. Alzheimer Res., 9, 864, 10.2174/156720512802455386 Zhu, 2007, Causes of oxidative stress in Alzheimer disease, Cell. Mol. Life Sci., 64, 2202, 10.1007/s00018-007-7218-4 Tonin, 2010, Long-chain 3-hydroxy fatty acids accumulating in LCHAD and MTP deficiencies induce oxidative stress in rat brain, Neurochem. Int., 56, 930, 10.1016/j.neuint.2010.03.025 Domingo, 2006, Aluminum and other metals in Alzheimer's disease: a review of potential therapy with chelating agents, J. Alzheimer's Dis., 331, 10.3233/JAD-2006-102-315 Rafii, 2009, Recent developments in Alzheimer's disease therapeutics, BMC Med., 7, 7, 10.1186/1741-7015-7-7 Wilcock, 2008, Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial, Lancet, 7, 483, 10.1016/S1474-4422(08)70090-5 Eriksen, 2003, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo, J. Clin. Invest., 112, 440, 10.1172/JCI18162 Myriad Genetics Reports Results of U.S., 2008 Green, 2009, Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial, JAMA, 302, 2557, 10.1001/jama.2009.1866 Imbimbo, 2009, Why did tarenflurbil fail in Alzheimer's disease?, J. Alzheimer's Dis., 17, 757, 10.3233/JAD-2009-1092 Swami, 2015, Adenosine conjugated lipidic nanoparticles for enhanced tumor targeting, Int. J. Pharm., 486, 287, 10.1016/j.ijpharm.2015.03.065 Win, 2005, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs, Biomaterials, 26, 2713, 10.1016/j.biomaterials.2004.07.050 Sahni, 2011, Neurotherapeutic applications of nanoparticles in Alzheimer's disease, J. Control. Release, 152, 208, 10.1016/j.jconrel.2010.11.033 Dora, 2012, Poly(ethylene glycol) hydroxystearate-based nanosized emulsions: effect of surfactant concentration on their formation and ability to solubilize quercetin, J. Biomed. Nanotechnol., 8, 202, 10.1166/jbn.2012.1380 Heurtault, 2002, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm. Res., 19, 875, 10.1023/A:1016121319668 Balls, 2004, Progressing toward the reduction, refinement and replacement of laboratory animal procedures: thoughts on some encounters with Dr Iain purchase, Toxicol. In Vitro, 18, 165, 10.1016/S0887-2333(03)00145-0 Horvat, 2009, Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue, Eur. J. Pharm. Biopharm., 72, 252, 10.1016/j.ejpb.2008.10.009 Amri, 2012, Administration of resveratrol: what formulation solutions to bioavailability limitations?, J. Control. Release, 158, 182, 10.1016/j.jconrel.2011.09.083 Ved, 2011, Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain, Int. J. Pharm., 411, 1, 10.1016/j.ijpharm.2011.02.040 Alexander, 2013, Poly(ethylene glycol)-poly(lactic-co-glycolic acid) based thermosensitive injectable hydrogels for biomedical applications, J. Control. Release, 172, 715, 10.1016/j.jconrel.2013.10.006 Picone, 2011, Insulin-activated Akt rescues Abeta oxidative stress-induced cell death by orchestrating molecular trafficking, Aging Cell, 10, 832, 10.1111/j.1474-9726.2011.00724.x Zhao, 2008, Amyloid beta oligomers induce impairment of neuronal insulin receptors, FASEB J., 22, 246, 10.1096/fj.06-7703com Di Carlo, 2010, Insulin promotes survival of amyloid-beta oligomers Neuroblastoma damaged cells via Caspase 9 inhibition and Hsp70 Upregulation, J. Biomed. Biotechnol., 2010, 8, 10.1155/2010/147835 Chua, 2012, Impaired neuronal insulin signaling precedes Abeta42 accumulation in female AbetaPPsw/PS1DeltaE9 mice, J. Alzheimer's Dis., 29, 783, 10.3233/JAD-2012-111880 Benedict, 2004, Intranasal insulin improves memory in humans, Psychoneuroendocrinology, 29, 1326, 10.1016/j.psyneuen.2004.04.003 Banks, 2004, The source of cerebral insulin, Eur. J. Pharmacol., 490, 5, 10.1016/j.ejphar.2004.02.040 Schulingkamp, 2000, Insulin receptors and insulin action in the brain: review and clinical implications, Neurosci. Biobehav. Rev., 24, 855, 10.1016/S0149-7634(00)00040-3 Wu, 2010, Multifunctional hybrid nanogel for integration of optical glucose sensing and self-regulated insulin release at physiological pH, ACS Nano, 4, 4831, 10.1021/nn1008319 Dispenza, 2015, Radiation-engineered functional nanoparticles in aqueous systems, J. Nanosci. Nanotechnol., 15, 3445, 10.1166/jnn.2015.9865 Picone, 2017, Nose-to-brain delivery of insulin enhanced by a nanogel carrier, J. Control. Release, 270, 23, 10.1016/j.jconrel.2017.11.040 Thorne, 2001, Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations, Clin. Pharmacokinet., 40, 907, 10.2165/00003088-200140120-00003 Graff, 2005, Nasal drug administration: potential for targeted central nervous system delivery, J. Pharm. Sci., 94, 1187, 10.1002/jps.20318 Dufes, 2003, Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats, Int. J. Pharm., 255, 87, 10.1016/S0378-5173(03)00039-5 Kim, 2000, In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion, Mol. Cells, 10, 142, 10.1007/s10059-000-0142-1 Nishimoto, 2004, Unravelling the role of Humanin, Trends Mol. Med., 10, 102, 10.1016/j.molmed.2004.01.001 Niikura, 2004, Humanin: after the discovery, Mol. Neurobiol., 30, 327, 10.1385/MN:30:3:327 Mamiya, 2001, [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo, Br. J. Pharmacol., 134, 1597, 10.1038/sj.bjp.0704429 Tajima, 2005, A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice, J. Neurosci. Res., 79, 714, 10.1002/jnr.20391 Garg, 2007, Cubosomes: an overview, Biol. Pharm. Bull., 30, 350, 10.1248/bpb.30.350 Li, 2007, Anti-infection peptidomics of amphibian skin, Mol. Cell. Proteomics, 6, 882, 10.1074/mcp.M600334-MCP200 Li, 2008, Odorranalectin is a small peptide lectin with potential for drug delivery and targeting, PLoS One, 3, 10.1371/journal.pone.0002381 Melgarejo Moreno, 1998, Olfactory epithelium of the rat. Lectin-mediated histochemical studies, An. Otorrinolaringol. Iberoam., 25, 471 Lundh, 1989, Lectin-binding pattern of neuroepithelial and respiratory epithelial cells in the mouse nasal cavity, Histochem. J., 21, 33, 10.1007/BF01002469 Spicer, 2001, Novel process for producing cubic liquid crystalline nanoparticles (Cubosomes), Langmuir, 17, 5748, 10.1021/la010161w Yue, 2007, Huperzine a in rat plasma and CSF following intranasal administration, Int. J. Pharm., 337, 127, 10.1016/j.ijpharm.2006.12.029 Tao, 2006, Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration, Yao xue xue bao, 41, 1104 Zhao, 2007, Drug brain distribution following intranasal administration of Huperzine a in situ gel in rats, Acta Pharmacol. Sin., 28, 273, 10.1111/j.1745-7254.2007.00486.x Majumdar, 2007, Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils, Mol. Biol. Cell, 18, 1490, 10.1091/mbc.e06-10-0975 Mitrasinovic, 2003, Microglial overexpression of the M-CSF receptor augments phagocytosis of opsonized Abeta, Neurobiol. Aging, 24, 807, 10.1016/S0197-4580(02)00237-3 Mitrasinovic, 2003, Macrophage colony stimulating factor promotes phagocytosis by murine microglia, Neurosci. Lett., 344, 185, 10.1016/S0304-3940(03)00474-9 Bartesaghi, 2005, Erythropoietin: a novel neuroprotective cytokine, Neurotoxicology, 26, 923, 10.1016/j.neuro.2005.01.016 Rabie, 2008, Brain protection by erythropoietin: a manifold task, Physiology (Bethesda, MD), 23, 263 Nadam, 2007, Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus, Neurobiol. Dis., 25, 412, 10.1016/j.nbd.2006.10.009 Sanchez, 2009, Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons, Proc. Natl. Acad. Sci. U. S. A., 106, 9848, 10.1073/pnas.0901840106 Assaraf, 2007, Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment, J. Neuropathol. Exp. Neurol., 66, 389, 10.1097/nen.0b013e3180517b28 Lee, 2006, Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage, J. Neurochem., 96, 1728, 10.1111/j.1471-4159.2006.03697.x Bernaudin, 1999, A potential role for erythropoietin in focal permanent cerebral ischemia in mice, J. Cereb. Blood Flow Metab., 19, 643, 10.1097/00004647-199906000-00007 Sakanaka, 1998, In vivo evidence that erythropoietin protects neurons from ischemic damage, Proc. Natl. Acad. Sci. U. S. A., 95, 4635, 10.1073/pnas.95.8.4635 Celik, 2002, Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury, Proc. Natl. Acad. Sci. U. S. A., 99, 2258, 10.1073/pnas.042693799 Brines, 2000, Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury, Proc. Natl. Acad. Sci., 97, 10526, 10.1073/pnas.97.19.10526 Li, 2004, Beneficial effect of erythropoietin on experimental allergic encephalomyelitis, Ann. Neurol., 56, 767, 10.1002/ana.20274 Kumral, 2004, Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats, Behav. Brain Res., 153, 77, 10.1016/j.bbr.2003.11.002 Grunfeld, 2007, Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model, Exp. Neurol., 204, 260, 10.1016/j.expneurol.2006.11.002 Chong, 2005, Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity, Curr. Neurovasc. Res., 2, 387, 10.2174/156720205774962683 Ma, 2009, Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway, Neuropharmacology, 56, 1027, 10.1016/j.neuropharm.2009.02.006 Garcia-Rodriguez, 2009, The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans, TheScientificWorldJOURNAL, 9, 970, 10.1100/tsw.2009.103 Maurice, 1996, Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction, Brain Res., 706, 181, 10.1016/0006-8993(95)01032-7 Bies, 2004, Lectin-mediated drug targeting: history and applications, Adv. Drug Deliv. Rev., 56, 425, 10.1016/j.addr.2003.10.030 Said, 1970, Polypeptide with broad biological activity: isolation from small intestine, Science (New York, N.Y.), 169, 1217, 10.1126/science.169.3951.1217 Magistretti, 1981, Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism, Proc. Natl. Acad. Sci. U. S. A., 78, 6535, 10.1073/pnas.78.10.6535 Muller, 1995, VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment, Mol. Neurobiol., 10, 115, 10.1007/BF02740671 Brenneman, 1998, VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide, Ann. N. Y. Acad. Sci., 865, 207, 10.1111/j.1749-6632.1998.tb11180.x Conner, 2009, NGF is essential for hippocampal plasticity and learning, J. Neurosci., 29, 10883, 10.1523/JNEUROSCI.2594-09.2009 Sanchez-Ortiz, 2012, TrkA gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry, J. Neurosci., 32, 4065, 10.1523/JNEUROSCI.6314-11.2012 Counts, 2011, Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer's disease, J. Chem. Neuroanat., 42, 111, 10.1016/j.jchemneu.2011.02.004 Morrison, 1986, Basic fibroblast growth factor supports the survival of cerebral cortical neurons in primary culture, Proc. Natl. Acad. Sci. U. S. A., 83, 7537, 10.1073/pnas.83.19.7537 Aoyagi, 1994, Characterization of basic fibroblast growth factor-mediated acceleration of axonal branching in cultured rat hippocampal neurons, Brain Res., 661, 117, 10.1016/0006-8993(94)91188-6 Terlau, 1990, Fibroblast growth factor enhances long-term potentiation in the hippocampal slice, Eur. J. Neurosc., Vol. 2, 973, 10.1111/j.1460-9568.1990.tb00009.x Sun, 2009, Basic fibroblast growth factor-enhanced neurogenesis contributes to cognitive recovery in rats following traumatic brain injury, Exp. Neurol., 216, 56, 10.1016/j.expneurol.2008.11.011 Yoshimura, 2003, FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice, J. Clin. Invest., 112, 1202, 10.1172/JCI16618 Kawamata, 1997, Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebralinfarction, Proc. Natl. Acad. Sci., 94, 8179, 10.1073/pnas.94.15.8179 Zechel, 2010, Expression and functions of fibroblast growth factor 2 (FGF-2) in hippocampal formation, Neuroscientist, 16, 357, 10.1177/1073858410371513 Stopa, 1990, Basic fibroblast growth factor in Alzheimer's disease, Biochem. Biophys. Res. Commun., 171, 690, 10.1016/0006-291X(90)91201-3 Mattson, 1997, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives, Physiol. Rev., 77, 1081, 10.1152/physrev.1997.77.4.1081 Baskin, 1997, Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures, J. Neurol. Sci., 148, 15, 10.1016/S0022-510X(96)05335-X Liu, 1999, Roles of p53, c-Myc, Bcl-2, Bax and caspases in glutamate-induced neuronal apoptosis and the possible neuroprotective mechanism of basic fibroblast growth factor, brain research, Mol. Brain Res., 71, 210, 10.1016/S0169-328X(99)00186-2 Illum, 2003, Nasal drug delivery—possibilities, problems and solutions, J. Control. Release, 87, 187, 10.1016/S0168-3659(02)00363-2 Wu, 2009, Lectins as tools in glycoconjugate research, Glycoconj. J., 26, 899, 10.1007/s10719-008-9119-7 Gabor, 2004, The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery, Adv. Drug Deliv. Rev., 56, 459, 10.1016/j.addr.2003.10.015 Pastor, 1992, Histochemical study of glycoconjugates in the nasal mucosa of the rat and Guinea pig, Histochem. J., 24, 727, 10.1007/BF01460825 Guzman-Casado, 2001, Myo-inositol hexasulphate and low molecular weight heparin binding to human acidic fibroblast growth factor: a calorimetric and FTIR study, Int. J. Biol. Macromol., 28, 305, 10.1016/S0141-8130(01)00131-3 Roghani, 1994, Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding, J. Biol. Chem., 269, 3976, 10.1016/S0021-9258(17)41730-3 Chafekar, 2007, Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation, Chembiochem, 8, 1857, 10.1002/cbic.200700338 Lowe, 2001, Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF, Biochemistry, 40, 7882, 10.1021/bi002734u Findeis, 1999, Modified-peptide inhibitors of amyloid beta-peptide polymerization, Biochemistry, 38, 6791, 10.1021/bi982824n Tjernberg, 1996, Arrest of beta-amyloid fibril formation by a pentapeptide ligand, J. Biol. Chem., 271, 8545, 10.1074/jbc.271.15.8545 Soto, 1998, Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy, Nat. Med., 4, 822, 10.1038/nm0798-822 Adessi, 2003, Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease, J. Biol. Chem., 278, 13905, 10.1074/jbc.M211976200 Chang, 2009, A new amyloid-like beta-aggregate with amyloid characteristics, except fibril morphology, J. Mol. Biol., 385, 1257, 10.1016/j.jmb.2008.11.009 Iwata, 2005, Metabolism of amyloid-beta peptide and Alzheimer's disease, Pharmacol. Ther., 108, 129, 10.1016/j.pharmthera.2005.03.010 Aileen Funke, 2010, Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's disease transgenic mice, ACS Chem. Neurosci., 1, 639, 10.1021/cn100057j Permanne, 2002, Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide, FASEB J., 16, 860, 10.1096/fj.01-0841fje Wiesehan, 2003, Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display, Chembiochem, 4, 748, 10.1002/cbic.200300631 Frydman-Marom, 2009, Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies, Angew. Chem., 48, 1981, 10.1002/anie.200802123 Lin, 2014, Feasibility of beta-sheet breaker peptide-H102 treatment for Alzheimer's disease based on beta-amyloid hypothesis, PLoS One, 9 Benedict, 2007, Intranasal insulin to improve memory function in humans, Neuroendocrinology, 86, 136, 10.1159/000106378 Lotjonen, 2011, Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease, NeuroImage, 56, 185, 10.1016/j.neuroimage.2011.01.062 Hanson, 2008, Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease, BMC Neurosci., 9, S5, 10.1186/1471-2202-9-S3-S5 Thorne, 1995, Quantitative analysis of the olfactory pathway for drug delivery to the brain, Brain Res., 692, 278, 10.1016/0006-8993(95)00637-6 Illum, 2004, Is nose-to-brain transport of drugs in man a reality?, J. Pharm. Pharmacol., 56, 3, 10.1211/0022357022539 Ali, 2010, Potential of nanoparticulate drug delivery systems by intranasal administration, Curr. Pharm. Des., 16, 1644, 10.2174/138161210791164108 Verma, 2010, Effect of surface properties on nanoparticle-cell interactions, Small, 6, 12, 10.1002/smll.200901158 Gozes, 2003, From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division, J. Mol. Neurosci., 20, 315, 10.1385/JMN:20:3:315 Gozes, 2004, NAP mechanisms of neuroprotection, J. Mol. Neurosci., 24, 67, 10.1385/JMN:24:1:067 Gozes, 2005, NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP), CNS Drug Rev., 11, 353, 10.1111/j.1527-3458.2005.tb00053.x Bassan, 1999, Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide, J. Neurochem., 72, 1283, 10.1046/j.1471-4159.1999.0721283.x Zemlyak, 2000, A novel peptide prevents death in enriched neuronal cultures, Regul. Pept., 96, 39, 10.1016/S0167-0115(00)00198-1 Beni-Adani, 2001, A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice, J. Pharmacol. Exp. Ther., 296, 57 Allen, 1999, Cellular internalization of PCL(20)-b-PEO(44) block copolymer micelles, Biochim. Biophys. Acta, 1421, 32, 10.1016/S0005-2736(99)00108-X Chonpathompikunlert, 2010, Br. Ind. Biol. Res. Assoc., 48, 798 Sastre, 2012, Local and systemic safety of intranasal corticosteroids, J Investig Allergol Clin Immunol, 22, 1 Illum, 1994, Chitosan as a novel nasal delivery system for peptide drugs, Pharm. Res., 11, 1186, 10.1023/A:1018901302450 Elnaggar, 2015, Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity, J. Pharm. Sci., 104, 3544, 10.1002/jps.24557 Alexander, 2016, Understanding the role of Poloxamer 407 based Thermoreversible in situ gelling hydrogel for delivery of PEGylated Melphalan conjugate, Curr. Drug Deliv., 13, 621, 10.2174/1567201813666160204114000 Mistry, 2009, Nanoparticles for direct nose-to-brain delivery of drugs, Int. J. Pharm., 379, 146, 10.1016/j.ijpharm.2009.06.019 Zhang, 2012, Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration, Eur. J. Pharm. Sci., 45, 632, 10.1016/j.ejps.2012.01.002 McNay, 2010, Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance, Neurobiol. Learn. Mem., 93, 546, 10.1016/j.nlm.2010.02.002 Schioth, 2012, Brain insulin signaling and Alzheimer's disease: current evidence and future directions, Mol. Neurobiol., 46, 4, 10.1007/s12035-011-8229-6 Chiu, 2008, Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo, Neuron, 58, 708, 10.1016/j.neuron.2008.04.014 Benedict, 2007, Intranasal insulin improves memory in humans: superiority of insulin aspart, Neuropsychopharmacology, 32, 239, 10.1038/sj.npp.1301193 Steen, 2005, Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes?, J. Alzheimer's Dis., 7, 63, 10.3233/JAD-2005-7107 Benedict, 2011, Intranasal insulin as a therapeutic option in the treatment of cognitive impairments, Exp. Gerontol., 46, 112, 10.1016/j.exger.2010.08.026 Reger, 2008, Intranasal insulin improves cognition and modulates beta-amyloid in early AD, Neurology, 70, 440, 10.1212/01.WNL.0000265401.62434.36 De Felice, 2009, Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers, Proc. Natl. Acad. Sci. U. S. A., 106, 1971, 10.1073/pnas.0809158106 Lee, 2009, Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation, Neurobiol. Aging, 30, 377, 10.1016/j.neurobiolaging.2007.06.014 Freiherr, 2013, Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence, CNS drugs, 27, 505, 10.1007/s40263-013-0076-8 Reger, 2006, Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype, Neurobiol. Aging, 27, 451, 10.1016/j.neurobiolaging.2005.03.016 Rangasamy, 2015, Intranasal delivery of NEMO-binding domain peptide prevents memory loss in a mouse model of Alzheimer's disease, J. Alzheimer's Dis., 47, 385, 10.3233/JAD-150040 Hayden, 2012, NF-kappaB, the first quarter-century: remarkable progress and outstanding questions, Genes Dev., 26, 203, 10.1101/gad.183434.111 Oeckinghaus, 2011, Crosstalk in NF-kappaB signaling pathways, Nat. Immunol., 12, 695, 10.1038/ni.2065 May, 2000, Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex, Science (New York, N.Y.), 289, 1550, 10.1126/science.289.5484.1550